Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

PMV Pharmaceuticals, Inc. PMVP NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$18.00
+1124.5%

PMV Pharmaceuticals, Inc. (PMVP) is a Biotechnology company in the Healthcare sector, currently trading at $1.47. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is PMVP = $18 (+1124.5% upside).

Valuation: PMVP trades at a trailing Price-to-Earnings (P/E) of -0.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.03.

Net income is $78M (loss), growing at -3.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $838,000 against $105M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 10.09 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $117M.

Analyst outlook: 4 / 4 analysts rate PMVP as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$18.00
▲ 1124.49% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for PMV Pharmaceuticals, Inc., the average price target is $18.00, with a high forecast of $36.00, and a low forecast of $5.00.
Highest Price Target
$36.00
Average Price Target
$18.00
Lowest Price Target
$5.00

PMVP SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PMVP

✓
VALUE Pass
100/100
PMVP trades at a trailing Price-to-Earnings (P/E) of -0.9 (S&P 500 average ~25). Forward PEG 0.03 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.01. Analyst consensus target is $18, implying +1124.5% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
PMVP: +0%/yr revenue is, -3.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet PMVP: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 10.09 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
PMVP: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 4 / 4 analysts rate PMVP as buy (100%). Analyst consensus target is $18 (+1124.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.81-1.88
Volume1.29M
Avg Volume (30D)627.83K
Market Cap$78.39M
Beta (1Y)1.40
Share Statistics
EPS (TTM)-1.48
Shares Outstanding$52.54M
IPO Date2020-09-25
Employees47
CEODavid H. Mack
Financial Highlights & Ratios
Gross Profit$-133K
EBITDA$-86.21M
Net Income$-77.74M
Operating Income$-86.21M
Total Cash$112.94M
Total Debt$838K
Net Debt$-37.15M
Total Assets$116.56M
Price / Earnings (P/E)-1
Analyst Forecast
1Y Price Target$15.50
Target High$36.00
Target Low$5.00
Upside+954.4%
Rating ConsensusBuy
Analysts Covering4
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS69353Y1038

Price Chart

Track all markets on TradingView
PMVP
PMV Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.81 52WK RANGE 1.88

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 TRDA
TRDA
Entrada Therapeutics, Inc.
$14.03
+1.01%
 VIGL
VIGL
Vigil Neuroscience, Inc.
$8.05
+0.00%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message